Compare SiTime Corporation (SITM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? SiTime Corporation trades at $510 (market cap $15.76B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: SiTime Corporation is far larger — about 3.1× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SITM | TVTX | |
|---|---|---|
Market Cap | $15.76B | $5.02B |
Volume | 697,177 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $901.60 | $67.52 |
52-Week Low | $252.76 | $26.79 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $15.17B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $579.66, up 1.68% today, showing strong momentum after recent earnings beats. The stock faces technical headwinds with bearish moving averages but benefits from unanimous analyst buy ratings and a $751.43 consensus price target. Recent Q2 2026 results showed 126.5% revenue growth to $157.43M and the company's first GAAP profit, driven by AI infrastructure demand and the Renesas acquisition.
The outlook remains positive with accelerating AI-driven growth, though high valuations (P/E 966.1) and negative 2025 net income ($-42.9M) pose risks. Institutional buying and strong Q3 guidance support upside potential, but investors should monitor execution on margin expansion and competitive pressures in the timing solutions market.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
